Researchers treat first cancer patients with BTG ’s microscopic, drug-loaded beads

Researchers from the UCL Cancer Institute and BTG (LON:BTG) have started the first clinical trial of microscopic beads loaded with a targeted, cancer-fighting drug for patients with primary liver cancer or metastatic colorectal cancer.
The trial is designed to evaluate the experimental therapy’s ability to deliver a precise amount of vandetanib directly to the arteries feeding a liver tumor using a radiopaque bead which can be seen on CT scans.
Get the full story at our sister site, Drug Delivery Business News.
The post Researchers treat first cancer patients with BTG’s microscopic, drug-loaded beads appeared first on MassDevice.

Source: Mass Device - October 10, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Pharmaceuticals Wall Street Beat BTG Source Type: news